Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 2
2010 6
2011 4
2012 4
2013 2
2014 5
2015 11
2016 11
2017 12
2018 22
2019 16
2020 19
2021 21
2022 39
2023 34
2024 19

Text availability

Article attribute

Article type

Publication date

Search Results

194 results

Results by year

Filters applied: . Clear all
Page 1
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.
Greenberg PL, Stone RM, Al-Kali A, Bennett JM, Borate U, Brunner AM, Chai-Ho W, Curtin P, de Castro CM, Deeg HJ, DeZern AE, Dinner S, Foucar C, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Jonas BA, Keel S, Madanat Y, Maness LJ, Mangan J, McCurdy S, McMahon C, Patel B, Reddy VV, Sallman DA, Shallis R, Shami PJ, Thota S, Varshavsky-Yanovsky AN, Westervelt P, Hollinger E, Shead DA, Hochstetler C. Greenberg PL, et al. Among authors: al kali a. J Natl Compr Canc Netw. 2022 Feb;20(2):106-117. doi: 10.6004/jnccn.2022.0009. J Natl Compr Canc Netw. 2022. PMID: 35130502
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors.
Numan Y, Abdel Rahman Z, Grenet J, Boisclair S, Bewersdorf JP, Collins C, Barth D, Fraga M, Bixby DL, Zeidan AM, Yilmaz M, Desai P, Mannis G, Deutsch YE, Abaza Y, Dinner S, Frankfurt O, Litzow M, Al-Kali A, Foran JM, Sproat LZ, Jovanovic B, Daver N, Perl AE, Altman JK. Numan Y, et al. Among authors: al kali a. Am J Hematol. 2022 Mar 1;97(3):322-328. doi: 10.1002/ajh.26447. Epub 2022 Jan 7. Am J Hematol. 2022. PMID: 34981560 Free article. Clinical Trial.
Autoimmune manifestations in STAG2-mutated myeloid neoplasms.
Katamesh B, Nanaa A, He R, Viswanatha D, Nguyen P, Greipp P, Foran J, Begna K, Gangat N, Patnaik M, Tefferi A, Litzow M, Mangaonkar A, Shah MV, Badar T, Alkhateeb HB, Al-Kali A. Katamesh B, et al. Among authors: al kali a. Ann Hematol. 2022 Dec;101(12):2785-2787. doi: 10.1007/s00277-022-04995-5. Epub 2022 Oct 3. Ann Hematol. 2022. PMID: 36184685 No abstract available.
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, Deeg HJ, Patel PA, Sabloff M, Keating MM, Zhu N, Gabrail NY, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern AE, O'Connell CL, Roboz GJ, Busque L, Buckstein R, Amin H, Randhawa J, Leber B, Shastri A, Dao KH, Oganesian A, Hao Y, Keer HN, Azab M, Savona MR. Garcia-Manero G, et al. Among authors: al kali a. Lancet Haematol. 2024 Jan;11(1):e15-e26. doi: 10.1016/S2352-3026(23)00338-1. Lancet Haematol. 2024. PMID: 38135371 Clinical Trial.
Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms.
Badar T, Nanaa A, Foran JM, Viswanatha D, Al-Kali A, Lasho T, Finke C, Alkhateeb HB, He R, Gangat N, Shah M, Tefferi A, Mangaonkar AA, Litzow MR, Ongie LJ, Chlon T, Ferrer A, Patnaik MM. Badar T, et al. Among authors: al kali a. Haematologica. 2023 Nov 1;108(11):3033-3043. doi: 10.3324/haematol.2023.282867. Haematologica. 2023. PMID: 37199125 Free PMC article. Review.
Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome.
Al-Kali A, Nanaa A, Viswanatha D, He R, Nguyen P, Jevremovic D, Foran JM, Yi CA, Greipp PT, Gangat N, Patnaik M, Tefferi A, Litzow MR, Mangaonkar AA, Shah MV, Badar T, Alkhateeb HB. Al-Kali A, et al. Blood Cancer J. 2023 Apr 10;13(1):49. doi: 10.1038/s41408-023-00818-6. Blood Cancer J. 2023. PMID: 37032414 Free PMC article. No abstract available.
Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes.
Martin ES, Ferrer A, Mangaonkar AA, Khan SP, Kohorst MA, Joshi AY, Hogan WJ, Olteanu H, Moyer AM, Al-Kali A, Tefferi A, Chen D, Wudhikarn K, Go R, Viswanatha D, He R, Ketterling R, Nguyen PL, Oliveira JL, Gangat N, Lasho T, Patnaik MM. Martin ES, et al. Among authors: al kali a. Am J Hematol. 2021 Nov 1;96(11):1450-1460. doi: 10.1002/ajh.26321. Epub 2021 Aug 27. Am J Hematol. 2021. PMID: 34390506 Free article.
The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms.
Gurney M, Chekkaf I, Baranwal A, Basmaci R, Katamesh B, Greipp P, Foran JM, Badar T, Mangaonkar AA, Begna KH, Gangat N, Patnaik MM, Litzow MR, Shah MV, Viswanatha DS, He R, Alkhateeb HB, Al-Kali A. Gurney M, et al. Among authors: al kali a. Br J Haematol. 2023 Jul;202(2):279-283. doi: 10.1111/bjh.18850. Epub 2023 May 5. Br J Haematol. 2023. PMID: 37144345
Comparison between GATA2 and DDX41-mutated myeloid neoplasms.
Nanaa A, He R, Viswanatha D, Nguyen P, Jevremovic D, Foran JM, Yi CA, Greipp PT, Gangat N, Patnaik M, Tefferi A, Litzow MR, Mangaonkar AA, Shah MV, Badar T, Alkhateeb HB, Al-Kali A. Nanaa A, et al. Among authors: al kali a. Leuk Res. 2022 Oct;121:106931. doi: 10.1016/j.leukres.2022.106931. Epub 2022 Aug 23. Leuk Res. 2022. PMID: 36037623 No abstract available.
Forodesine: review of preclinical and clinical data.
Al-Kali A, Gandhi V, Ayoubi M, Keating M, Ravandi F. Al-Kali A, et al. Future Oncol. 2010 Aug;6(8):1211-7. doi: 10.2217/fon.10.83. Future Oncol. 2010. PMID: 20799866 Review.
194 results